You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞信:蔓迪銷售強於預期,上調三生製藥(1530.HK)目標價至11港元
格隆匯 06-30 13:24

瑞信發表報吿,將三生製藥(1530.HK)目標價由9港元升至11港元,投資評級由跑贏大市降至中性。

報吿指,高瓴出售了其在三生製藥的股份,導致公司股價在6月25日下跌16.7%,給該股帶來壓力。管理層透露高瓴減持為意料之外,事前未有通知。

報吿又指,公司治療脱髮外用藥蔓迪(Mandi)上半年銷售強於預期,預計今年銷售額將達到8億元人民幣。同時管理層預期市場上血小板生成素受體激動劑(TPO-RA)產品,不太對特比澳構成威脅,因為目前未有TPO-RA產品獲批用於治療血小板減少症。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account